EKTA B Elekta AB Class B

Elekta to Highlight High Definition Dynamic Radiosurgery Solutions for Faster, More Precise Stereotactic Treatments at Astro Annual Meeting

At the American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28 in Boston, Elekta (EKTA-B.ST) will showcase HD Dynamic Radiosurgery, a unique capability, leveraging the core strengths of Versa HD™ linear accelerator (http://www.elekta.com/versahd) and Monaco® (https://www.elekta.com/software-solutions/treatment-management/external-beam-planning/monaco.html) treatment planning system.

Versa HD combines High Definition Dynamic Radiosurgery treatment capabilities and precision radiotherapy in a single platform. Equipped with sophisticated full-field, high definition beam-shaping technology and High Dose Rate mode, Versa HD offers the precision and speed necessary to deliver versatile stereotactic treatments throughout the body. Monaco powers more efficient high definition planning with true Monte Carlo accuracy and advanced multi-criterial optimization.

The powerful combination of Versa HD and Monaco enables more modulation in a single arc with 1,024 dynamic control points enabling delivery of highly-conformal stereotactic radiosurgery and stereotactic body radiotherapy treatments within standard treatment slots, irrespective of complexity or anatomy.

Visitors to Elekta booth #7017 also will have an opportunity to learn more about:

· MOSAIQ® Oncology Analytics, a knowledge management solution that unlocks data into actionable information to enable continuous improvement of clinical, operational and financial performance.

· Leksell Gamma Knife® Icon™ (http://www.careforthebrain.com/), the latest technological advance in Elekta’s Gamma Knife gold standard radiosurgery platform, enables precision cranial radiosurgery with online dose adaptation. Featuring sophisticated imaging and motion management technologies, Icon is making cranial radiosurgery available to more patients by offering frameless fractionated treatments with similar accuracy as frame-based single-session radiosurgery.

· Venezia™*, Elekta’s new gynecological applicator provides a new option for treating advanced-stage cervical cancer. Designed to support the recommendations for 3D image-guided adaptive brachytherapy for locally advanced cervical cancer, Venezia uniquely allows clinicians to treat IIIA and IIIB tumors in the cervix, parametrium and vaginal extensions through a combination of straight and oblique needles with consistent and reproducible needle placement.

· Advanced imaging and motion management solutions, which allow more focused guidance for precise dose targeting and critical structure avoidance. XVI 4D reduces margins with online automated motion guidance and increases precision through critical structure avoidance. Clarity Autoscan® delivers precise intra-fraction motion management for prostate featuring continuous soft-tissue imaging.

“We believe that our innovative offerings in oncology informatics and image-guided treatment solutions will positively impact the management of cancer and neurological disease,” said Richard Hausmann, PhD, President and CEO. “Through our solutions, services and support, we provide our customers with the tools to focus where it matters, improving efficiency, quality and patient outcomes.”

Additional Elekta activities

The 25th Annual Elekta Users Meeting (EUM) convenes Saturday, September 24 at the Sheraton Boston Hotel. Customers using any Elekta solution are welcome to participate in this free educational opportunity. To learn more about the EUM, visit www.elekta.com/EUM2016.

Elekta’s Capital Markets Presentation will be held Monday, September 26 from 9 - 11:30 a.m. at the Renaissance Boston Waterfront. Richard Hausmann and other members of the management team will highlight the company’s solutions portfolio. Visit www.elekta.com/investors to watch live.

Elekta is a Premier Corporate sponsor of the 2016 American Society of Radiologic Technologists (ASRT) Radiation Therapy Conference and will be at booth #15 on the 3rd floor, Gloucester Room of the Boston Marriott Copley Place.

Elekta supports the Society for Radiation Oncology Administrators (SROA) as a Titanium sponsor and will exhibit at the SROA 33rd Annual Meeting on the Mezzanine Level, Grand Ballroom of the Boston Park Plaza Hotel, booth #18. In addition, Elekta is sponsoring the SROA President’s Party Tuesday, September 27 at the Boston Park Plaza Hotel.

Follow the Elekta Twitter handle, @Elekta, for updates from the ASTRO show floor. To learn more about Elekta at ASTRO, visit www.elekta.com/ASTRO.

*Venezia is not available for sale or distribution in all markets, is not for sale in the United States and is pending 510(k) clearance.

# # #

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

This information was brought to you by Cision http://news.cision.com

EN
21/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Elekta AB Class B

Elekta AB: 1 director

A director at Elekta AB bought 3,150 shares at 76.860SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK82.00) - A soft quarter

Q3 earnings were softer than we and the market expected. The weak order intake stood out, while strong cash flow was the bright spot in the report. Order intake (c14% below our forecast and consensus) remains hampered by still-poor performance in APAC (mainly China). EMEA was also weak, but on very challenging comparables. Overall, the company was optimistic that Q4 would be in line with last year, bolstering the share price. We reiterate our HOLD, but have trimmed our target price to SEK82 (SEK...

Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK83.00) - Still on the sidelines

After a disappointing Q2, we forecast Q3 2023/24 to show an improvement (results due at 07:30 CET on 29 February), although we still expect a soft quarter, with declining order intake YOY. Overall, we have made some negative revisions to our forecasts ahead of the report, and reiterate our HOLD, but have lowered our target price to SEK83 (90).

Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK90.00) - Soft Q2 gross margin

Reported Q2 earnings overall were in line or better than our forecast. The earnings beat (c7% above consensus on adj. EBIT and 3% above our estimate) was driven by lower operating expenses, with the largest deviation seen in R&D expenses, where the capitalisation of R&D costs was above our forecast. The gross margin missed our estimate by 220bp and consensus by 230bp. Order intake was in line with consensus but c3% below our forecast. We reiterate our HOLD but have trimmed our target price to SE...

Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK92.00) - We expect an undramatic report

For the Q2 report, we expect the market to focus on the gross margin trend and order intake. Management stated with the Q1 report the gross margin would come down QOQ, but the question is by how much, as the sales mix looks to have changed for the worse. Comments on the implications of the ViewRay bankruptcy should also be in focus, as well as the possibility of Elekta converting some of its order backlog to Unity systems instead. We reiterate our HOLD, but have raised our target price to SEK92 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch